METROPOLISMetropolis Healthcare Limited
Healthcare · Diagnostics & Research · NSE · as of 2026-10-26 (delayed ~30 min in market hours)
Metropolis Healthcare Limited, together with its subsidiaries, provides pathology and related healthcare services in India, Africa, South Asia, the Middle East, and internationally. The company offers routine and semi-specialised pathology tests; advanced diagnostics, including genetic, molecular, and cytogenetic testing; preventive healthcare packages and corporate wellness screening; and clinical trial research, hospital lab management, and home collection services, as well as profiles, blood tests, and soft radiology services. It also provides diagnostic services for oncology, neurology, gynecology, and nephrology, as well as various health check-up packages for men, women, senior citizens, youth, and corporates. In addition, the company develops and deals in technology driven products and services. The company serves a range of customers, including direct-to-consumer diagnostics through patient service centers, a mobile app, a website, and home collection; partnerships with standalone labs, hospital chains, and diagnostic networks; and institutional clients, such as corporates, government bodies, and hospital lab management services. Metropolis Healthcare Limited was founded in 1980 and is headquartered in Mumbai, India.
Price & Volume
Loading chart…
Key Ratios
“—” means the figure isn't meaningful or isn't published for this company: ROE and Debt/Equity are undefined when shareholder equity is negative (check P/B — negative means negative equity), and DII/MF holding splits aren't provided by our current data source.
Active Pattern Signals
None of the 16 pattern scanners currently detects a setup on METROPOLIS — signals appear here automatically when one forms (checked on every data refresh). The Trade Plan on the right always provides stop-loss and target levels regardless.
The picture
- • Revenue growth: 16.6% YoY
- • Debt/Equity: 0.15
- • Promoter holding: 47.8%
- • MACD: fresh bullish crossover
- • Price vs SMA200: above
- • Golden cross setup: SMA50 above SMA200
Bull case
- • Revenue growth: 16.6% YoY
- • Debt/Equity: 0.15
- • Promoter holding: 47.8%
- • MACD: fresh bullish crossover
Bear case
- • PEG ratio: 4.23
- • Dividend yield: 0.35%
- • Price vs EMA21: below
- • Price vs SMA50: below
Key risks
- • Momentum is fading versus the broader market
- • PEG ratio: 4.23
- • Dividend yield: 0.35%
Algorithmic analysis for research only — not SEBI-registered investment advice.
Trade Plan
Stop = 20-day support with a 2.5×ATR risk cap (ATR ₹19.98). Levels recompute on every data refresh. Position sizing and execution are yours — this is analysis, not advice.